Skip To Main Content
Christos Evangelou on Muck Rack

Christos Evangelou

(He/Him)
San Diego, United States
As seen in: Nature, Medscape, Medscape France, Medscape Noticias Médicas, Medscape PT, EyeNet Magazine, Internal Medicine News, MDedge Hematology and Oncology, MDEdge, EMJ- European Medical Journal and
Covers:  Health, Science, Medicine
Freelance medical writer and medical communications consultant with a passion for science and health. #MedComms #SciComm #MedRight #Health #Science

Get in touch with Christos

Contact Christos, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Christos Evangelou’s Biography

Read Full Bio →

As a freelance medical writer and editor, I help researchers from academia and biotech to translate their complex science into clear, compelling, and high-impact messages for the scientific community and the wider public.

After working as a scientist in cancer research for ten years, I decided to switch gears and start a career as a medical writer and editor. I am passionate about communicating science, helping academic and biotech research groups translate new research findings into treatments…

Christos Evangelou’s Journalist Portfolio

See all →
Cautious optimism for new Alzheimer's disease biomarkers and treatments, expert says

Cautious optimism for new Alzheimer's disease biomarkers and treatments, expert says

SAN DIEGO - said a presenter at the annual meeting of the American College of Physicians. Dementia prevalence…

View article →

View article →
T-DXd Effective in HR+/HER2-Low BC After Endocrine Failure

T-DXd Effective in HR+/HER2-Low BC After Endocrine Failure

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with …

View article →
Nab-Paclitaxel Shows Edge in High-Risk BC Subgroup

Nab-Paclitaxel Shows Edge in High-Risk BC Subgroup

Weekly nab-paclitaxel demonstrated improved disease-free survival compared with biweekly standard paclitaxel …

View article →
Atezolizumab Plus Chemo Misses Mark in TNBC

Atezolizumab Plus Chemo Misses Mark in TNBC

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival …

View article →
Exploratory Analysis Identifies Biomarkers of Response in TNBC

Exploratory Analysis Identifies Biomarkers of Response in TNBC

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab i…

View article →

Articles

Induction Immunotherapy Has Durable Survival Benefit in Locally Advanced Cervical Cancer

|
By Christos Evangelou
| Medscape Verified
Giving dual checkpoint blockade ahead of chemoradiation yields a high 3-year survival rate for patients with locally advanced cervical cancer, particularly for those with “hot” tumors, according to updated data from the phase 2 COLIBRI-1 trial. Among 40 patients with locally advanced cervical cancer who were treated with one cycle of nivolumab/ipilimumab before standard chemoradiation, overall survival was 90% at 3 years.
Open in Who Shared Issue with article?

Mirvetuximab Fails to Boost Survival in Platinum-Eligible Ovarian Cancer

|
By Christos Evangelou
| Medscape Verified
The antibody-drug conjugate (ADC) mirvetuximab soravtansine boosts tumor response when added to standard chemotherapy for patients with platinum-sensitive ovarian cancer, but it does not improve their survival outcomes, according to a phase 2 trial. Mirvetuximab is currently approved as monotherapy for patients with platinum-resistant ovarian cancer that’s folate receptor (FR) alpha-positive after they’ve received one to three prior systemic therapies.
Open in Who Shared Issue with article?

Rucaparib Delays Next Lines of Therapy in Ovarian Cancer

|
By Christos Evangelou
| Medscape Verified
For patients with advanced ovarian cancer, first-line maintenance therapy with rucaparib delays the need for first and second subsequent therapies by roughly a year at each step, according to new data from the phase 3 ATHENA-MONO trial. Among patients randomized to rucaparib after surgery and standard chemotherapy, the median time to first subsequent therapy was just under 24 months vs 12 months among patients randomized to placebo.
Open in Who Shared Issue with article?
See all 233 articles